Latest News - GenSight Biologics

Wednesday, January 10, 2018 | Clinical Trials, Retina, GenSight Biologics

GenSight Biologics Receives MHRA Approval to Initiate Phase 1/2 PIONEER Clinical Trial of Gene Therapy in Retinitis Pigmentosa

GenSight Biologics announced that the UK Medicines and Healthcare Regulatory Agency (MHRA) has accepted the company’s clinical trial application (CTA) to initiate the PIONEER phase 1/2 study of …

Read the full story

Wednesday, June 14, 2017 | Clinical Trials, GenSight Biologics

GenSight Biologics Reports Long-Term Results in Phase 1/2 Study of GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy

GenSight Biologics reported additional promising clinical trial results with GS010 after 96 weeks of follow-up in its phase 1/2 study. These results confirm the long-term positive sustained visual acu…

Read the full story